Thoratec Corporation Announces First Quarter Earnings Conference Call, Web Cast

Apr 16, 2001, 01:00 ET from Thoratec Corporation

    PLEASANTON, Calif., April 16 /PRNewswire/ --
 Thoratec Corporation (Nasdaq: THOR), a medical device company, today announced
 that it will report its operating results for the first quarter of fiscal
 2001 on Tuesday, April 24.  This will be the first quarterly results report
 since the company completed its merger with Thermo Cardiosystems in
 mid-February.
     The news release will be followed by a conference call and web cast to
 discuss financial results and operating activities open to all interested
 parties at 1 p.m., Pacific Daylight Time, Tuesday, April 24, hosted by
 D. Keith Grossman, president and chief executive officer; and Cheryl Hess,
 vice president and chief financial officer.
     The teleconference can be accessed by calling 719-457-2657.  Please dial
 in ten to fifteen minutes prior to the beginning of the call.  The web cast
 will be available via the Internet at www.thoratec.com or
 www.videonewswire.com/THORATEC/042401.
     A replay of the conference call will be available through May 8, via
 www.thoratec.com or by calling 719-457-0820.  The access code for the replay
 is 474755.
     Formerly known as Thoratec Laboratories, the company is engaged in the
 research, development, manufacturing and marketing of medical devices for
 circulatory support and vascular graft applications.  The Thoratec(R)
 Ventricular Assist Device (VAD) System is the only ventricular assist device
 that is approved for use both as a bridge-to-transplant and for recovery from
 open-heart surgery and has been used in the treatment of more than
 1,500 patients.  The company is also a leader in the research, development and
 manufacturer of implantable left ventricular assist systems (LVAS).  Its
 air-driven and electric HeartMate(R) heart assist device, which are approved
 for sale in the U.S., Europe and Canada, are implanted alongside the natural
 heart and take over the pumping function of the left ventricle for patients
 whose hearts are too damaged or diseased to produce adequate blood flow.
     The company's other products include the Vectra(TM) vascular access graft,
 which is used in patients undergoing hemodialysis, and is approved for sale in
 the U.S., Europe and Japan and a number of other foreign countries.  Its
 Aria(TM) coronary artery bypass graft, which is designed for use by patients
 having too few suitable native blood vessels, is currently in clinical trials
 in the U.S.  The company's International Technidyne division supplies
 whole-blood coagulation testing equipment and related disposables, as well as
 single-use skin-incision devices.  Headquartered in Pleasanton, California,
 the company also has facilities in Woburn and Chelmsford, Massachusetts,
 Rancho Cordova, California and Edison, New Jersey.  For more information,
 visit the company's web sites at http://www.thoratec.com or
 http://www.itcmed.com .
 
 

SOURCE Thoratec Corporation
    PLEASANTON, Calif., April 16 /PRNewswire/ --
 Thoratec Corporation (Nasdaq: THOR), a medical device company, today announced
 that it will report its operating results for the first quarter of fiscal
 2001 on Tuesday, April 24.  This will be the first quarterly results report
 since the company completed its merger with Thermo Cardiosystems in
 mid-February.
     The news release will be followed by a conference call and web cast to
 discuss financial results and operating activities open to all interested
 parties at 1 p.m., Pacific Daylight Time, Tuesday, April 24, hosted by
 D. Keith Grossman, president and chief executive officer; and Cheryl Hess,
 vice president and chief financial officer.
     The teleconference can be accessed by calling 719-457-2657.  Please dial
 in ten to fifteen minutes prior to the beginning of the call.  The web cast
 will be available via the Internet at www.thoratec.com or
 www.videonewswire.com/THORATEC/042401.
     A replay of the conference call will be available through May 8, via
 www.thoratec.com or by calling 719-457-0820.  The access code for the replay
 is 474755.
     Formerly known as Thoratec Laboratories, the company is engaged in the
 research, development, manufacturing and marketing of medical devices for
 circulatory support and vascular graft applications.  The Thoratec(R)
 Ventricular Assist Device (VAD) System is the only ventricular assist device
 that is approved for use both as a bridge-to-transplant and for recovery from
 open-heart surgery and has been used in the treatment of more than
 1,500 patients.  The company is also a leader in the research, development and
 manufacturer of implantable left ventricular assist systems (LVAS).  Its
 air-driven and electric HeartMate(R) heart assist device, which are approved
 for sale in the U.S., Europe and Canada, are implanted alongside the natural
 heart and take over the pumping function of the left ventricle for patients
 whose hearts are too damaged or diseased to produce adequate blood flow.
     The company's other products include the Vectra(TM) vascular access graft,
 which is used in patients undergoing hemodialysis, and is approved for sale in
 the U.S., Europe and Japan and a number of other foreign countries.  Its
 Aria(TM) coronary artery bypass graft, which is designed for use by patients
 having too few suitable native blood vessels, is currently in clinical trials
 in the U.S.  The company's International Technidyne division supplies
 whole-blood coagulation testing equipment and related disposables, as well as
 single-use skin-incision devices.  Headquartered in Pleasanton, California,
 the company also has facilities in Woburn and Chelmsford, Massachusetts,
 Rancho Cordova, California and Edison, New Jersey.  For more information,
 visit the company's web sites at http://www.thoratec.com or
 http://www.itcmed.com .
 
 SOURCE  Thoratec Corporation